Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Variants/Loss-of-function

Loss-of-function

CIViC ID: 132 · Gene: BRCA2

Variant Summary

HGVS: —
Variant Type(s): loss_of_function_variant
Evidence Items: 11

Evidence Level Distribution

Level A: 3Level B: 6Level D: 2

Evidence Items

Showing CIViC evidence rows where gene = BRCA2 and variant = Loss-of-function.

Level	Type	Direction	Significance	Disease	Drugs	Rating
A	Predictive	Supports	Sensitivity/Response	Her2-receptor Negative Breast Cancer	Olaparib	5
A	Predictive	Supports	Sensitivity/Response	Triple-receptor Negative Breast Cancer	Olaparib	5
A	Predictive	Supports	Sensitivity/Response	Pancreatic Adenocarcinoma	Olaparib	5
D	Predictive	Supports	Sensitivity/Response	Breast Cancer	Quarfloxin,Pidnarulex	4
B	Predictive	Supports	Sensitivity/Response	Ovarian Cancer	Olaparib	4
B	Predictive	Supports	Sensitivity/Response	Breast Cancer	Talazoparib	4
B	Predictive	Supports	Sensitivity/Response	Prostate Cancer	Olaparib	4
B	Prognostic	Supports	Poor Outcome	Prostate Cancer		3
B	Predictive	Supports	Sensitivity/Response	Ovarian Cancer	Talazoparib	3
B	Predictive	Supports	Sensitivity/Response	Her2-receptor Negative Breast Cancer	Olaparib	3
D	Predictive	Supports	Sensitivity/Response	Pancreatic Cancer	Mitomycin	2